Details of the Drug

General Information of Drug (ID: DMBTGNN)

Drug Name

BNT111

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Vaccine

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04526899) Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma. U.S.National Institutes of Health.